Physician profile
John E Pierce
NPI 1598755712
$2,295.56
in general payments reported to CMS, 2019-2025
37 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $183 · 2021: $321 · 2022: $461 · 2023: $419 · 2024: $158 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.83 | 2021-2023 | |
| Pfizer INC. | $217.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $181.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $171.75 | 2019-2023 | Spravato |
| Novo Nordisk INC | $158.34 | 2019-2023 | Ozempic, Rybelsus |
| Dexcom, INC. | $127.77 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.55 | 2019-2023 | Xifaxan |
| Exact Sciences Corporation | $91.37 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $90.92 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Amgen INC. | $88.34 | 2019-2023 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $88.08 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $81.22 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $80.16 | 2022-2025 | |
| Allergan, INC. | $69.80 | 2019-2020 | |
| Amarin Pharma, INC. | $68.06 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $64.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.56 | 2019-2024 | |
| Lilly USA, LLC | $31.29 | 2019-2023 | Mounjaro |
| Eisai INC. | $26.98 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $25.25 | 2021-2022 | |
| Inspire Medical Systems, INC. | $22.74 | 2025 | Inspire |
| Medline Industries Lp | $20.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.25 | 2022 | |
| Si-Bone, INC. | $18.49 | 2025 | |
| Axsome Therapeutics, INC. | $17.22 | 2023 | Sunosi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.90 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.57 | 2024 | Opsumit, Uptravi |
| Mannkind Corporation | $16.56 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.88 | 2021 | |
| Almatica Pharma LLC | $14.32 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.00 | 2019 | |
| Corium, LLC | $12.98 | 2023 | Azstarys |
| Glaxosmithkline, LLC. | $12.25 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.39 | 2021 | |
| Biogen, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.